Cargando…

The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists

OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and rankin...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Joshua J, Fitzgerald, Paul B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088334/
https://www.ncbi.nlm.nih.gov/pubmed/36779819
http://dx.doi.org/10.1177/10398562231156684
_version_ 1785022556984573952
author Berger, Joshua J
Fitzgerald, Paul B
author_facet Berger, Joshua J
Fitzgerald, Paul B
author_sort Berger, Joshua J
collection PubMed
description OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions. RESULTS: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future. CONCLUSION: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.
format Online
Article
Text
id pubmed-10088334
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100883342023-04-12 The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists Berger, Joshua J Fitzgerald, Paul B Australas Psychiatry Psychotropic Medication OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions. RESULTS: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future. CONCLUSION: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists. SAGE Publications 2023-02-13 2023-04 /pmc/articles/PMC10088334/ /pubmed/36779819 http://dx.doi.org/10.1177/10398562231156684 Text en © The Royal Australian and New Zealand College of Psychiatrists 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Psychotropic Medication
Berger, Joshua J
Fitzgerald, Paul B
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title_full The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title_fullStr The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title_full_unstemmed The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title_short The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
title_sort prescription of psychedelic therapies in australia and new zealand: a brief survey of psychiatrists
topic Psychotropic Medication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088334/
https://www.ncbi.nlm.nih.gov/pubmed/36779819
http://dx.doi.org/10.1177/10398562231156684
work_keys_str_mv AT bergerjoshuaj theprescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists
AT fitzgeraldpaulb theprescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists
AT bergerjoshuaj prescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists
AT fitzgeraldpaulb prescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists